[1]
|
中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志, 2023, 38(6): 583-612.
|
[2]
|
Arora, S., Stouffer, G.A., Kucharska-Newton, A., et al. (2019) Twenty Year Trends and Sex Differences in Young Adults Hospitalized with Acute Myocardial Infarction: The ARIC Community Surveillance Study. Circulation, 138, 1047-1056. https://doi.org/10.1161/CIRCULATIONAHA.118.037137
|
[3]
|
Ahmad, O., Boschipinto, C., Lopez, A., et al. (2001) Age Standardization of Rates: A New WHO Standard. Global Programme on Evidence for Health Policy Discussion Paper Series: No. 31. https://doi.org/10.17016/IFDP.2001.712
|
[4]
|
Smith, C.L., Seigerman, M., Adusumalli, S., et al. (2021) Evolution and Outcomes of Premature Coronary Artery Disease. Current Cardiology Reports, 23, Article No. 36. https://doi.org/10.1007/s11886-021-01457-8
|
[5]
|
Wang, X., Gao, M., Zhou, S., et al. (2017) Trend in Young Coronary Artery Disease in China from 2010 to 2014: A Retrospective Study of Young Patients ≤ 45. BMC Cardiovascular Disorders, 17, Article No. 18. https://doi.org/10.1186/s12872-016-0458-1
|
[6]
|
Hoogeveen, R.C. and Ballantyne, C.M. (2021) Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clinical Chemistry, 67, 143-153. https://doi.org/10.1093/clinchem/hvaa252
|
[7]
|
Tada, H., Takamura, M. and Kawashiri, M.A. (2019) Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis, 26, 583-591. https://doi.org/10.5551/jat.RV17034
|
[8]
|
Burgess, S., Ference, B.A., et al. (2018) Association of LPA Variants with Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiology, 3, 619-627. https://doi.org/10.1001/jamacardio.2018.1470
|
[9]
|
Nordestgaard, B.G. and Langsted, A. (2016) Thematic Review Series: Lipoprotein (a): Coming of Age at Last: Lipoprotein (a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology. Journal of Lipid Research, 57, 1953-1975. https://doi.org/10.1194/jlr.R071233
|
[10]
|
Enas, E.A., Varkey, B., Dharmarajan, T.S., Pare, G. and Bahl, V.K. (2019) Lipoprotein(a): An Independent, Genetic, and Causal Factor for Cardiovascular Disease and Acute Myocardial Infarction. Indian Heart Journal, 71, 99-112. https://doi.org/10.1016/j.ihj.2019.03.004
|
[11]
|
周鹏, 王烁, 任艳玲. 冠心病患者冠状动脉CT特征与血清脂蛋白(a)、脂联素、PTX3的相关性研究[J]. 分子诊断与治疗杂志, 2020, 12(2): 244-248.
|
[12]
|
桑国耀, 王丽娟, 张裕祥. 血清sCD14、Lp(a)、Gal-3与冠状动脉粥样硬化血管内皮功能及斑块易损性的关系分析[J]. 临床和实验医学杂志, 2023, 22(18): 1929-1934.
|
[13]
|
Kaiser, Y., Daghem, M., Tzolos, E., et al. (2022) Association of Lipoprotein(a) with Atherosclerotic Plaque Progression. Journal of the American College of Cardiology, 79, 223-233. https://doi.org/10.1016/j.jacc.2021.10.044
|
[14]
|
Chua, S.K., Hung, H.F., Shyu, K.G., et al. (2010) Acute ST-Elevation Myocardial Infarction in Young Patients: 15 Years of Experience in a Single Center. Clinical Cardiology, 33, 140-148. https://doi.org/10.1002/clc.20718
|
[15]
|
Zeitouni, M., Clare, R.M., Chiswell, K., et al. (2020) Risk Factor Burden and Long-Term Prognosis of Patients with Premature Coronary Artery Disease. Journal of the American Heart Association, 9, e017712. https://doi.org/10.1161/JAHA.120.017712
|
[16]
|
郑刚. 冠状动脉粥样硬化斑块特征与临床预后相关性研究的进展[J]. 中华老年心脑血管病杂志, 2020, 22(3): 317-320.
|
[17]
|
申华, 张黛, 杜俣, 等. 光学相干断层成像下青年女性急性冠状动脉综合征患者的斑块特征分析[J]. 心肺血管病杂志, 2019, 38(4): 365-369.
|
[18]
|
Rallidis, L.S., Pavlakis, G., Foscolou, A., et al. (2018) High Levels of Lipoprotein (a) and Premature Acute Coronary Syndrome. Atherosclerosis, 269, 29-34. https://doi.org/10.1016/j.atherosclerosis.2017.12.011
|
[19]
|
付琳, 李瑾. 载脂蛋白基因多态性与冠心病发病风险关系的研究进展[J]. 中西医结合心脑血管病杂志, 2022, 20(4): 667-672.
|
[20]
|
北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12): 1158-1167.
|
[21]
|
Zekavat, S.M., Ruotsalainen, S., Handsaker, R.E., et al. (2020) Publisher Correction: Deep Coverage Whole Genome Sequences and Plasma Lipoprotein(a) in Individuals of European and African Ancestries. Nature Communications, 11, Article No. 1715. https://doi.org/10.1038/s41467-020-15236-6
|
[22]
|
Cybulska, B., Kosiewicz-Latoszek, L., Penson, P.E., et al. (2020) What Do We Know About The Role of Lipoprotein(a) in Atherogenesis 57 Years after Its Discovery? Progress in Cardiovascular Diseases, 63, 219-227. https://doi.org/10.1016/j.pcad.2020.04.004
|
[23]
|
Sharma, M., Redpath, G.M., Williams, M.J.A., et al. (2017) Recycling of Apolipoprotein(a) after PlgRKT-Mediated Endocytosis Lipoprotein(a). Circulation Research, 120, 1091-1102. https://doi.org/10.1161/CIRCRESAHA.116.310272
|
[24]
|
Marcovina, S.M. and Albers, J.J. (2016) Lipoprotein(a) Measurements for Clinical Application. Journal of Lipid Research, 57, 526-537. https://doi.org/10.1194/jlr.R061648
|
[25]
|
Tsimikas, S. (2017) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. https://doi.org/10.1016/j.jacc.2016.11.042
|
[26]
|
Kronenberg, F., Mora, S., Stroes, E.S.G., et al. (2022) Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal, 43, 3925-3946. https://doi.org/10.1093/eurheartj/ehac361
|
[27]
|
Björnson, E., Adiels, M., Taskinen, M.R., et al. (2024) Lipoprotein(a) Is Markedly More Atherogenic than LDL: An Apolipoprotein B-Based Genetic Analysis. Journal of the American College of Cardiology, 83, 385-395. https://doi.org/10.1016/j.jacc.2023.10.039
|
[28]
|
Marston, N.A., Melloni, G.E.M., Murphy, S.A.,et al. (2024) Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins. Journal of the American College of Cardiology, 83, 470-472. https://doi.org/10.1016/j.jacc.2023.09.836
|
[29]
|
Tsimikas, S. and Bittner, V. (2024) Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB: Perspectives on Contributions to ASCVD. Journal of the American College of Cardiology, 83, 396-400. https://doi.org/10.1016/j.jacc.2023.11.008
|
[30]
|
Kiechl, S. and Willeit, J. (2010) The Mysteries of Lipoprotein(a) and Cardiovascular Disease Revisited. Journal of the American College of Cardiology, 55, 2168-2170. https://doi.org/10.1016/j.jacc.2009.12.048
|
[31]
|
Labudovic, D., Kostovska, I., Trajkovska, K.T., et al. (2019) Lipoprotein(a)—Link between Atherogenesis and Thrombosis. Prague Medical Report, 120, 39-51. https://doi.org/10.14712/23362936.2019.9
|
[32]
|
Sabbah, N., Jaisson, S., Garnotel, R., et al. (2019) Small Size Apolipoprotein(a) Isoforms Enhance Inflammatory and Proteolytic Potential of Collagen-Primed Monocytes. Lipids in Health and Disease, 18, Article No. 166. https://doi.org/10.1186/s12944-019-1106-4
|
[33]
|
Jang, A.Y., Han, S.H., Sohn, I.S., et al. (2020) Lipoprotein(a) and Cardiovascular Diseases—Revisited. Circulation Journal, 84, 867-874. https://doi.org/10.1253/circj.CJ-20-0051
|
[34]
|
Van Der Valk, F.M., Bekkering, S., Kroon, J., et al. (2016) Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 134, 611-624. https://doi.org/10.1161/CIRCULATIONAHA.116.020838
|
[35]
|
Knig, M., Joshi, S., Leistner, D.M., et al. (2019) Cohort Profile: Role of Lipoproteins in Cardiovascular Disease—The LipidCardio Study. BMJ Open, 9, e030097. https://doi.org/10.1136/bmjopen-2019-030097
|
[36]
|
Coassin, S. and Kronenberg, F. (2022) Lipoprotein(a) beyond the Kringle IV Repeat Polymorphism: The Complexity of Genetic Variation in the LPA Gene. Atherosclerosis, 349, 17-35. https://doi.org/10.1016/j.atherosclerosis.2022.04.003
|
[37]
|
Schmidt, K., Noureen, A., Kronenberg, F. and Utermann, G. (2016) Structure, Function, and Genetics of Lipoprotein(a). Journal of Lipid Research, 57, 1339-1359. https://doi.org/10.1194/jlr.R067314
|
[38]
|
Ruscica, M., Sirtori, C., Corsini, A., et al. (2021) Lipoprotein(a): Knowns, Unknowns and Uncertainties. Pharmacological Research, 173, Article ID: 105812. https://doi.org/10.1016/j.phrs.2021.105812
|
[39]
|
Emdin, C.A., Khera, A.V., Natarajan, P., et al. (2016) Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. Journal of the American College of Cardiology, 68, 2761-2772. https://doi.org/10.1016/j.jacc.2016.10.033
|
[40]
|
Thanassoulis, G., Campbell, C.Y., Owens, D.S., et al. (2013) Genetic Associations with Valvular Calcification and Aortic Stenosis. The New England Journal of Medicine, 368, 503-512. https://doi.org/10.1056/NEJMoa1109034
|
[41]
|
Jubran, A., Zetser, A. and Zafrir, B. (2019) Lipoprotein(a) Screening in Young and Middle-Aged Patients Presenting with Acute Coronary Syndrome. Cardiology Journal, 26, 511-518. https://doi.org/10.5603/CJ.a2018.0106
|
[42]
|
Zewinger, S., Kleber, M.E., Tragante, V., et al. (2017) Relations between Lipoprotein(a) Concentrations, LPA Genetic Variants, and the Risk of Mortality in Patients with Established Coronary Heart Disease: A Molecular and Genetic Association Study. The Lancet Diabetes & Endocrinology, 5, 534-543. https://doi.org/10.1016/S2213-8587(17)30096-7
|
[43]
|
Mack, S., Coassin, S., Rueedi, R., et al. (2017) A Genome-Wide Association Meta-Analysis on Lipoprotein(a) Concentrations Adjusted for Apolipoprotein(a) Isoforms. Journal of Lipid Research, 58, 1834-1844. https://doi.org/10.1194/jlr.M076232
|
[44]
|
Zhao, J., Feng, Q.P., Wu, P., et al. (2018) Using Topic Modeling via Non-Negative Matrix Factorization to Identify Relationships between Genetic Variants and Disease Phenotypes: A Case Study of Lipoprotein(a) (LPA). Cold Spring Harbor Laboratory, 14, e0212112. https://doi.org/10.1101/335745
|
[45]
|
Erbel, R. and Budoff, M. (2012) Improvement of Cardiovascular Risk Prediction Using Coronary Imaging: Subclinical Atherosclerosis: The Memory of Lifetime Risk Factor Exposure. European Heart Journal, 33, 1201-1213. https://doi.org/10.1093/eurheartj/ehs076
|
[46]
|
Cardoso-Saldaa, G., Fragoso, J.M., Lale-Farjat, S., et al. (2019) The Rs10455872-G Allele of the LPA Gene Is Associated with High Lipoprotein(a) Levels and Increased Aortic Valve Calcium in a Mexican Adult Population. Genetics and Molecular Biology, 42, 519-525. https://doi.org/10.1590/1678-4685-gmb-2017-0371
|
[47]
|
Arsenault, B.J., Boekholdt, S.M., Dubé, M.P., et al. (2014) Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis a Prospective Mendelian Randomization Study and Replication in a Case-Control Cohort. Circulation: Cardiovascular Genetics, 7, 304-310. https://doi.org/10.1161/CIRCGENETICS.113.000400
|
[48]
|
Pechlivanis, S., Mahabadi, A.A., Hoffmann, P., et al. (2020) Association between Lipoprotein(a) (Lp(a)) Levels and Lp(a) Genetic Variants with Coronary Artery Calcification. BMC Medical Genetics, 21, Article No. 62. https://doi.org/10.1186/s12881-020-01003-3
|
[49]
|
Gencer, B., Kronenberg, F., Stroes, E.S., et al. (2017) Lipoprotein(a): The Revenant. European Heart Journal, 38, 1553-1560. https://doi.org/10.1093/eurheartj/ehx033
|
[50]
|
Claudia, L., Kronenberg, F., et al. (2019) Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes—A Mendelian Randomization Analysis. JAMA Cardiology, 4, 575-579. https://doi.org/10.1001/jamacardio.2019.1041
|
[51]
|
Reyes-Soffer, G., Ginsberg, H.N., Berglund, L., et al. (2022) Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, e48-e60. https://doi.org/10.1161/ATV.0000000000000147
|
[52]
|
Farmakis, I., Doundoulakis, I., Pagiantza, A., et al. (2021) Lipoprotein(a) Reduction with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Pharmacology, 77, 397-407. https://doi.org/10.1097/FJC.0000000000000963
|
[53]
|
Ruscica, M., Tokgozoglu, L., Corsini, A., et al. (2019) PCSK9 Inhibition and Inflammation: A Narrative Review. Atherosclerosis, 288, 146-155. https://doi.org/10.1016/j.atherosclerosis.2019.07.015
|
[54]
|
Parish, S., Hopewell, J.C., Hill, M.R., et al. (2018) Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. Circulation: Genomic and Precision Medicine, 11, e001696. https://doi.org/10.1161/CIRCGEN.117.001696
|
[55]
|
Nissen, S., Wolski, K., Balog, C., et al. (2022) Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals with Elevated Plasma Lipoprotein(a) Levels. JAMA, 327, 1679-1687. https://doi.org/10.1001/jama.2022.5050
|
[56]
|
Mehta, A. and Shapiro, M.D. (2022) Apolipoproteins in Vascular Biology and Atherosclerotic Disease. Nature Reviews Cardiology, 19, 168-179. https://doi.org/10.1038/s41569-021-00613-5
|